a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

This study is testing a new CAR-T cell therapy called CT0596 in patients with multiple myeloma (a blood cancer of plasma cells) or plasma cell leukemia that has come back or stopped responding to previous treatments. CAR-T therapy uses your own immune cells, which are genetically engineered in a lab to recognize and kill cancer cells. **You may be eligible if...** - You are 18 years or older - You have relapsed or treatment-resistant multiple myeloma and have already tried at least 3 prior treatment regimens including at least one proteasome inhibitor and one immunomodulator - You have relapsed or treatment-resistant plasma cell leukemia and have tried at least 1 prior treatment - Your cancer has measurable signs of active disease - Your expected survival is at least 12 weeks - You are in good enough physical condition (ECOG score 0-1) **You may NOT be eligible if...** - Your organ function is poor (liver, kidney, heart, or lungs) - You have active uncontrolled infection or autoimmune disease - You are pregnant or unwilling to use contraception for 1 year after treatment Talk to your doctor to see if this trial is right for you.